Larimar Therapeutics Q3 EPS $(0.29) Beats $(0.35) Estimate
Benzinga Newsdesk 4 days ago
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 17.14 percent. This is a 52.46 percent increase over losses of $(0.61) per share
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 17.14 percent. This is a 52.46 percent increase over losses of $(0.61) per share from the same period last year.
